Joan Merrill, EULAR 2021: Findings from the TULIP-1 and TULIP-2 Trials in SLE
TouchIMMUNOLOGY were delighted to talk with Dr Joan Merrill (University of Oklahoma Health Sciences Center, Oklahoma City, OK, US) around the use of anifrolumab in the treatment of rash and arthritis in patients with SLE and the impact of IFN gene signatures on treatment response.
The abstract ‘Anifrolumab Effects on Rash and Arthritis in Patients With SLE and Impact of Interferon Signal in Pooled Data From Phase 3 Trials.‘ (OP0131), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- What is the rationale for the use of anifrolumab in the treatment of rash and arthritis in patients with SLE? (0:29)
- What have we learned from the MUSE and TULIP studies about the clinical utility of anifrolumab in the treatment of patients with SLE? (1:15)
- What were the aims of the analysis of pooled data from the TULIP-1 and TULIP-2 trials? (1:45)
- What were the findings of this analysis in patients who were IFN gene signature (IFNGS) test high and low? (2:47)
- What were the limitations of this study and what future studies are planned? (4:02)
Disclosures: Joan Merrill has consulted for Astra Zeneca and received grant funding from Astra Zeneca for research. Additionally in past two years Joan Merrill has received grant funding from Bristol Myers Squibb, Glaxo Smith Kline, and consulted for both of those companies as well as Abbvie, Alexion, Alpine, Amgen, Astellas, Aurinia, Biogen, EMD Serono, Genentech, Immupharma, Janssen, Lilly, Remegen, Provention, Sanofi, UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!